Our findings bring forth new insights into the role of CrkL on Dox resistance to myelogenous leukemia, and further studies are needed to confirm CrkL as a potential therapeutic target for myelogenous leukemia patients with chemoresistance. This evidence concerns the gene CRKL and myeloid leukemia.